Agilent Technologies, Inc.
A
Classement en actions
#504
Agilent Technologies, Inc. delivers specialized, application-focused... Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
Prix de l'action
$169.80
Dernière synchronisation: 2026-10-19
Capitalisation boursière
$47.88B
Changement (1 jour)
-1.75%
Changement (1 an)
18.74%
Pays
US
Échange Agilent Technologies, Inc. (A)
Catégorie
Healthcare
Ratio P/E pour Agilent Technologies, Inc. (A)
Ratio P/E au October 2026 TTM : 34.18
Selon les derniers rapports financiers et le cours de l'action de Agilent Technologies, Inc., le ratio P/E actuel (TTM) est de 34.18. À la fin de l’année 2024, le P/E de l’entreprise était de 29.32.
Historique du ratio P/E pour Agilent Technologies, Inc. de 2000 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | 34.18 | 7.53% |
| 2025 | 31.79 | 8.43% |
| 2024 | 29.32 | 19.62% |
| 2023 | 24.51 | -25.70% |
| 2022 | 32.99 | -16.40% |
| 2021 | 39.46 | -10.06% |
| 2020 | 43.87 | 97.56% |
| 2019 | 22.21 | -66.26% |
| 2018 | 65.82 | 105.51% |
| 2017 | 32.03 | 3.72% |
| 2016 | 30.88 | -1.53% |
| 2015 | 31.36 | 30.78% |
| 2014 | 23.98 | 40.24% |
| 2013 | 17.10 | 120.07% |
| 2012 | 7.77 | -14.53% |
| 2011 | 9.09 | -27.90% |
| 2010 | 12.61 | -106.38% |
| 2009 | -197.44 | -2,475.14% |
| 2008 | 8.31 | -48.91% |
| 2007 | 16.27 | 420.46% |
| 2006 | 3.13 | -95.86% |
| 2005 | 75.57 | 246.76% |
| 2004 | 21.79 | -664.77% |
| 2003 | -3.86 | -7.51% |
| 2002 | -4.17 | -110.20% |
| 2001 | 40.89 | 120.97% |
| 2000 | 18.51 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 36.15 | 5.76% |
US
|
|
| 39.77 | 16.35% |
US
|
|
| -290.26 | -949.09% |
US
|
|
| - | - |
CN
|
|
| 37.15 | 8.67% |
US
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.